Using artificial intelligence (AI) to supplement radiologists’ evaluations of mammograms may improve breast-cancer screening by reducing false positives without missing cases of cancer, according to a study by researchers at Washington University School of Medicine in St. Louis and Whiterabbit.ai, a Silicon Valley-based technology startup.
Credit: Debbie Bennett/Washington University
Using artificial intelligence (AI) to supplement radiologists’ evaluations of mammograms may improve breast-cancer screening by reducing false positives without missing cases of cancer, according to a study by researchers at Washington University School of Medicine in St. Louis and Whiterabbit.ai, a Silicon Valley-based technology startup.
The researchers developed an algorithm that identified normal mammograms with very high sensitivity. They then ran a simulation on patient data to see what would have happened if all of the very low-risk mammograms had been taken off radiologists’ plates, freeing the doctors to concentrate on the more questionable scans. The simulation revealed that fewer people would have been called back for additional testing but that the same number of cancer cases would have been detected.
“False positives are when you call a patient back for additional testing, and it turns out to be benign,” explained senior author Richard L. Wahl, MD, a professor of radiology at Washington University’s Mallinckrodt Institute of Radiology (MIR) and a professor of radiation oncology. “That causes a lot of unnecessary anxiety for patients and consumes medical resources. This simulation study showed that very low-risk mammograms can be reliably identified by AI to reduce false positives and improve workflows.”
The study is published April 10 in the journal Radiology: Artificial Intelligence.
Wahl previously collaborated with Whiterabbit.ai on an algorithm to help radiologists judge breast density on mammograms to identify people who could benefit from additional or alternative screening. That algorithm received clearance from the Food and Drug Administration (FDA) in 2020 and is now marketed by Whiterabbit.ai as WRDensity.
In this study, Wahl and colleagues at Whiterabbit.ai worked together to develop a way to rule out cancer using AI to evaluate mammograms. They trained the AI model on 123,248 2D digital mammograms (containing 6,161 showing cancer) that were largely collected and read by Washington University radiologists. Then, they validated and tested the AI model on three independent sets of mammograms, two from institutions in the U.S. and one in the United Kingdom.
First, the researchers figured out what the doctors did: how many patients were called back for secondary screening and biopsies; the results of those tests; and the final determination in each case. Then, they applied AI to the datasets to see what would have been different if AI had been used to remove negative mammograms in the initial assessments and physicians had followed standard diagnostic procedures to evaluate the rest.
For example, consider the largest dataset, which contained 11,592 mammograms. When scaled to 10,000 mammograms (to make the math simpler for the purposes of the simulation), AI identified 34.9% as negative. If those 3,485 negative mammograms had been removed from the workload, radiologists would have made 897 callbacks for diagnostic exams, a reduction of 23.7% from the 1,159 they made in reality. At the next step, 190 people would have been called in a second time for biopsies, a reduction of 6.9% from the 200 in reality. At the end of the process, both the AI rule-out and real-world standard-of-care approaches identified the same 55 cancers. In other words, this study of AI suggests that out of 10,000 people who underwent initial mammograms, 262 could have avoided diagnostic exams, and 10 could have avoided biopsies, without any cancer cases being missed.
“At the end of the day, we believe in a world where the doctor is the superhero who finds cancer and helps patients navigate their journey ahead,” said co-author Jason Su, co-founder and chief technology officer at Whiterabbit.ai. “The way AI systems can help is by being in a supporting role. By accurately assessing the negatives, it can help remove the hay from the haystack so doctors can find the needle more easily. This study demonstrates that AI can potentially be highly accurate in identifying negative exams. More importantly, the results showed that automating the detection of negatives may also lead to a tremendous benefit in the reduction of false positives without changing the cancer detection rate.”
Journal
Radiology Artificial Intelligence
DOI
10.1148/ryai.230033
Method of Research
Computational simulation/modeling
Subject of Research
People
Article Title
A Semi-autonomous Deep Learning System to Reduce False-Positives in Screening Mammography.
Article Publication Date
10-Apr-2024
COI Statement
S.P. Employee of Whiterabbit.ai; stock/stock options in Whiterabbit.ai. T.T. Support from Whiterabbit.ai; patents planned, issued, or pending with Whiterabbit.ai; stock/stock options in Whiterabbit.ai. B.M. Support from Whiterabbit.ai; patents planned, issued, or pending with Whiterabbit.ai; stock/stock options in Whiterabbit.ai; other financial or nonfinancial interests in Whiterabbit.ai. Y.N.T.V. Support from Whiterabbit.ai; stock/stock options in Whiterabbit.ai. T.M. Employee of Whiterabbit.ai; support for attending meetings/travel from Whiterabbit.ai; patents planned, issued, or pending with Whiterabbit.ai; stock/stock options in Whiterabbit.ai. R.M.H. Employee of Whiterabbit.ai; stock/stock options in Whiterabbit.ai; laptop and monitors provided by Whiterabbit.ai. M.S. Support from Whiterabbit.ai. N.G. Employee of Whiterabbit.ai; stock/stock options in Whiterabbit.ai. N.Z.D. Employee of Whiterabbit.ai; support for attending meetings/travel from Whiterabbit.ai; stock/stock options in Whiterabbit.ai. S.H. Intermittent consultant for Whiterabbit.ai and Therapixel regarding AI in breast imaging. C.M.A. Serve as a consultant to Whiterabbit.ai but not compensated directly for work pertinent to this manuscript; payments made for general product development, quality control considerations and providing general subject matter expertise; board member of nonprofit organization Pink Ribbon Good (nonpaid position); stock options in Whiterabbit.ai. J.S. Employee of Whiterabbit.ai, salary payments and equity compensation; Support for travel to conferences to participate in presentations related to this work from Whiterabbit.ai; inventor on filed patents related to this work with Whiterabbit.ai; officer of the company and member of board of directors with Whiterabbit.ai; stock compensation from Whiterabbit.ai as part of employment agreement. R.L.W. Research contract payment from Whiterabbit.ai for providing image data with Washington University School of Medicine; Washington University has the potential for receiving royalties if the software is eventually FDA approved and sold; past president and board of directors of SNMMI; Washington University has a small fractional ownership position in Whiterabbit.ai. These shares are not traded as the company is not public.